SCHEMBL3678417

SCHEMBL3678417

COCCOCOc1cccn(-c2c(C)cc([N+](=O)[O-])cc2C)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 1/20 0.36
ALDH1A1 P00352 8/20 0.36
LMNA P02545 3/20 0.36
MAPT P10636 5/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HTT P42858 3/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
PKM P14618 3/20 0.35
HPGD P15428 3/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3421400 0.88 F2RL3 (0.39) F2RL3ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL3678355 0.84 F2 (0.33) ALDH1A1MAPTHTTHPGD
SCHEMBL3424022 0.81 ALDH1A1 (0.43) ALDH1A1LMNAMAPTSMN1; SMN2HTT
SCHEMBL13896875 0.81 F2RL3 (0.39) F2RL3ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL13272130 0.77 F2RL3 (0.36) F2RL3ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL3419912 0.77 F2RL3 (0.36) F2RL3ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL3419910 0.77 F2RL3 (0.36) F2RL3ALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL27909201 0.75 RECQL (0.45) ALDH1A1MAPTSMN1; SMN2HTTGAA
SCHEMBL3423017 0.74 MAPT (0.33) ALDH1A1LMNAMAPTGAAMEN1
SCHEMBL3644238 0.71 ALDH1A1 (0.43) ALDH1A1LMNAMAPTHTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
EP-2167499-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Schering Pharma AG (DE) 2010-03-31 EP disclosed
WO-2008155069-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, OXA1L, PPOX F2RL3 1495/4885ALDH1A1 441/4885LMNA 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.